J. M. Erb

发表

4-Oxospiro[benzopyran-2,4′-piperidines] as selective α1a-adrenergic receptor antagonists

M. Bock, R. Chang, T. Broten, 1999 .

Design and synthesis of N-alkylated saccharins as selective α-1a adrenergic receptor antagonists☆

R. Chang, Tsing-bau Chen, J. Huff, 1998 .

1-(((7,7-Dimethyl-2(S)-(2(S)-amino-4-(methylsulfonyl)butyramido) bicyclo(2.2.1)heptan-1(S)-yl)methyl)sulfonyl)-4-(2-methylphenyl) piperazine (L-368,899): An Orally Bioavailable, Non-Peptide Oxytocin Antagonist with Potential Utility for Managing Preterm Labor.

B. E. Evans, M. Bock, R. Freidinger, 1994 .

1-((7,7-Dimethyl-2(S)-(2(S)-amino-4-(methylsulfonyl)butyramido)bicyclo [2.2.1]-heptan-1(S)-yl)methyl)sulfonyl)-4-(2-methylphenyl)piperaz ine (L-368,899): an orally bioavailable, non-peptide oxytocin antagonist with potential utility for managing preterm labor.

B. E. Evans, M. Bock, P. Anderson, 1994, Journal of medicinal chemistry.

3-Phosphinic acid and 3-phosphonic acid steroids as inhibitors of steroid 5α-reductase: Species comparison and mechanistic studies

L. Rozamus, D. Holt, B. Metcalf, 1991 .

1-(1-[4-[(N-acetyl-4-piperidinyl)oxy]-2-methoxybenzoyl]piperidin-4- yl)-4H-3,1-benzoxazin-2(1H)-one (L-371,257): a new, orally bioavailable, non-peptide oxytocin antagonist.

D. Veber, R. Freidinger, D. Reiss, 1995, Journal of medicinal chemistry.

Development of a novel class of cyclic hexapeptide oxytocin antagonists based on a natural product.

M. Bock, W. L. Whitter, G. F. Lundell, 1992, Journal of medicinal chemistry.

Palladium-catalyzed phosphorylation of alkenyl triflates

D. Holt, J. M. Erb, 1989 .

Use of N-Fmoc amino acid chlorides and activated 2-(fluorenylmethoxy)-5(4H)-oxazolones in solid-phase peptide synthesis. Efficient syntheses of highly N-alkylated cyclic hexapeptide oxytocin antagonists related to L-365,209

Roger M. Freidinger, Peter D. Williams, D. Veber, 1992 .

Cyclic hexapeptide oxytocin antagonists. Potency-, selectivity-, and solubility-enhancing modifications.

M. Bock, R. M. Dipardo, R. Freidinger, 1990, Journal of medicinal chemistry.

Potent inhibition of human steroid 5α-reductase (EC 1.3.1.30) by 3-androstene-3-carboxylic acids

D. Holt, B. Metcalf, H. Oh, 1989 .

Steroidal A ring aryl carboxylic acids: a new class of steroid 5 alpha-reductase inhibitors.

D. Holt, B. Metcalf, H. Oh, 1990, Journal of medicinal chemistry.

Steroidal A Ring Aryl Carboxylic Acids: A New Class of Steroid 5α-Reductase Inhibitors.

D. Holt, B. Metcalf, H. Oh, 1990 .

Development of orally active oxytocin antagonists: studies on 1-(1-[4-[1-(2-methyl-1-oxidopyridin-3-ylmethyl)piperidin-4-yloxy]-2- methoxybenzoyl]piperidin-4-yl)-1,4-dihydrobenz[d][1,3]oxazin-2-one (L-372,662) and related pyridines.

S Vickers, R. Freidinger, D. Reiss, 1998, Journal of medicinal chemistry.

Inhibition of steroid 5 alpha-reductase by unsaturated 3-carboxysteroids.

D. Holt, H. Lan-Hargest, B. Metcalf, 1990, Journal of medicinal chemistry.

Conformationally constrained o-tolylpiperazine camphorsulfonamide oxytocin antagonists. Structural modifications that provide high receptor affinity and suggest a bioactive conformation.

D. Veber, R. Freidinger, R. Ball, 1994, Bioorganic & medicinal chemistry.

Novel oxytocin antagonists

B. E. Evans, D. Veber, M. Bock, 1993 .

Potent and selective cyclic hexapeptide oxytocin antagonists

D. Veber, M. Bock, R. M. Dipardo, 1991 .

Potent and Selective Oxytocin Antagonists Obtained by Chemical Modification of a Streptomyces Silvensis Derived Cyclic Hexapeptide and by Total Synthesis

D. Veber, M. Bock, R. M. Dipardo, 1990 .

Orally active, non-peptide oxytocin antagonists

B. E. Evans, D. Veber, M. Bock, 1994 .